<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SYPRINE- trientine hydrochloride capsule </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<h1>
<span class="Bold">SYPRINE<span class="Sup">®</span></span><br><span class="Bold"> (TRIENTINE HYDROCHLORIDE)</span><br><span class="Bold">Capsules</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_58d1f8b5-c605-4d12-8a78-7c17e7d001af"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Trientine hydrochloride is <span class="Italics">N,N'</span>-bis (2-aminoethyl)-1,2-ethanediamine dihydrochloride. It is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline hygroscopic powder. It is freely soluble in water, soluble in methanol, slightly soluble in ethanol, and insoluble in chloroform and ether.</p>
<p>The empirical formula is C<span class="Sub">6</span>H<span class="Sub">18</span>N<span class="Sub">4</span>•2HCl with a molecular weight of 219.2. The structural formula is:</p>
<p>          NH<span class="Sub">2</span>(CH<span class="Sub">2</span>)<span class="Sub">2</span>NH(CH<span class="Sub">2</span>)<span class="Sub">2</span>NH(CH<span class="Sub">2</span>)<span class="Sub">2</span>NH<span class="Sub">2</span>•2HCl</p>
<p>Trientine hydrochloride is a chelating compound for removal of excess copper from the body. SYPRINE<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> (Trientine Hydrochloride) is available as 250 mg capsules for oral administration. Capsules SYPRINE contain gelatin, iron oxides, stearic acid, and titanium dioxide as inactive ingredients.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>SYPRINE is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates. © 2014 Valeant Pharmaceuticals International, Inc. or its affiliates. All rights reserved.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5578ddec-0b8d-4111-bc0c-18e886645ee9"></a><a name="section-2.1"></a><p></p>
<h2>Introduction</h2>
<p class="First">Wilson's disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d857d814-d173-4ed6-9af2-2b266632bf90"></a><a name="section-2.2"></a><p></p>
<h2>Clinical Summary</h2>
<p class="First">Forty-one patients (18 male and 23 female) between the ages of 6 and 54 with a diagnosis of Wilson's disease and who were intolerant of d-penicillamine were treated in two separate studies with trientine hydrochloride. The dosage varied from 450 to 2400 mg per day. The average dosage required to achieve an optimal clinical response varied between 1000 mg and 2000 mg per day. The mean duration of trientine hydrochloride therapy was 48.7 months (range 2-164 months). Thirty-four of the 41 patients improved, 4 had no change in clinical global response, 2 were lost to follow-up and one showed deterioration in clinical condition. One of the patients who improved while on therapy with trientine hydrochloride experienced a recurrence of the symptoms of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> which had appeared originally during therapy with penicillamine. Therapy with trientine hydrochloride was discontinued. No other adverse reactions, except <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, were noted among any of these 41 patients.</p>
<p>One investigator treated 13 patients with trientine hydrochloride following their development of intolerance to d-penicillamine. Retrospectively, he compared these patients to an additional group of 12 patients with Wilson's disease who were both tolerant of and controlled with d-penicillamine therapy, but who failed to continue any copper chelation therapy. The mean age at onset of disease of the latter group was 12 years as compared to 21 years for the former group. The trientine hydrochloride group received d-penicillamine for an average of 4 years as compared to an average of 10 years for the non-treated group.</p>
<p>Various laboratory parameters showed changes in favor of the patients treated with trientine hydrochloride. Free and total serum copper, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, and serum bilirubin all showed mean increases over baseline in the untreated group which were significantly larger than with the patients treated with trientine hydrochloride. In the 13 patients treated with trientine hydrochloride, previous symptoms and signs relating to d-penicillamine intolerance disappeared in 8 patients, improved in 4 patients, and remained unchanged in one patient. The neurological status in the trientine hydrochloride group was unchanged or improved over baseline, whereas in the untreated group, 6 patients remained unchanged and 6 worsened. Kayser-Fleischer rings improved significantly during trientine hydrochloride treatment.</p>
<p>The clinical outcome of the two groups also differed markedly. Of the 13 patients on therapy with trientine hydrochloride (mean duration of therapy 4.1 years; range 1 to 13 years), all were alive at the data cutoff date, and in the non-treated group (mean years with no therapy 2.7 years; range 3 months to 9 years), 9 of the 12 died of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b21db900-62ed-4dd9-83db-6b3a2ea35b1d"></a><a name="section-2.3"></a><p></p>
<h2>Chelating Properties</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cd784727-22d2-4d57-a2fa-6406f79491cd"></a><a name="section-2.3.1"></a><p></p>
<h3>Preclinical Studies</h3>
<p class="First">Studies in animals have shown that trientine hydrochloride has cupriuretic activities in both normal and copper-loaded rats. In general, the effects of trientine hydrochloride on urinary copper excretion are similar to those of equimolar doses of penicillamine, although in one study they were significantly smaller.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4f559573-557d-4273-a12f-71977f5e8bbb"></a><a name="section-2.3.2"></a><p></p>
<h3>Human Studies</h3>
<p class="First">Renal clearance studies were carried out with penicillamine and trientine hydrochloride on separate occasions in selected patients treated with penicillamine for at least one year. Six-hour excretion rates of copper were determined off treatment and after a single dose of 500 mg of penicillamine or 1.2 g of trientine hydrochloride. The mean urinary excretion rates of copper were as follows:</p>
<table>
<col width="15%">
<col width="25%">
<col width="30%">
<col width="30%">
<thead><tr class="First Last">
<th class="Botrule Toprule">
<span class="Bold">No. of </span><br><span class="Bold">Patients</span>
</th>
<th class="Botrule Toprule"><span class="Bold">Single Dose Treatment</span></th>
<th class="Botrule Toprule">
<span class="Bold">Basal Excretion Rate </span><br><span class="Bold">(µg Cu + + /6hr)</span>
</th>
<th class="Botrule Toprule">
<span class="Bold">Test-dose Excretion Rate </span><br><span class="Bold">(µg Cu + + /6hr)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top"><p class="First">6</p></td>
<td class="Toprule" valign="top"><p class="First">Trientine, 1.2 g</p></td>
<td class="Toprule" valign="top"><p class="First">19</p></td>
<td class="Toprule" valign="top"><p class="First">234</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">4</p></td>
<td class="Botrule" valign="top"><p class="First">Penicillamine, 500mg</p></td>
<td class="Botrule" valign="top"><p class="First">17</p></td>
<td class="Botrule" valign="top"><p class="First">320</p></td>
</tr>
</tbody>
</table>
<p>In patients <span class="Italics">not</span> previously treated with chelating agents, a similar comparison was made: </p>
<table>
<col width="15%">
<col width="25%">
<col width="30%">
<col width="30%">
<thead><tr class="First Last">
<th class="Botrule Toprule"><span class="Bold">No. of  Patients</span></th>
<th class="Botrule Toprule"><span class="Bold">Single Dose Treatment</span></th>
<th class="Botrule Toprule">
<span class="Bold">Basal Excretion Rate </span><br><span class="Bold">(µg Cu + + /6hr)</span>
</th>
<th class="Botrule Toprule">
<span class="Bold">Test-dose Excretion Rate </span><br><span class="Bold">(µg Cu + + /6hr)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top"><p class="First">8</p></td>
<td class="Toprule" valign="top"><p class="First">Trientine, 1.2 g</p></td>
<td class="Toprule" valign="top"><p class="First">71</p></td>
<td class="Toprule" valign="top"><p class="First">1326</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">7</p></td>
<td class="Botrule" valign="top"><p class="First">Penicillamine, 500mg</p></td>
<td class="Botrule" valign="top"><p class="First">68</p></td>
<td class="Botrule" valign="top"><p class="First">1074</p></td>
</tr>
</tbody>
</table>
<p>These results demonstrate that SYPRINE is effective as a cupriuretic agent in patients with Wilson's disease although on a molar basis it appears to be less potent or less effective than penicillamine. Evidence from a radio-labelled copper study indicates that the different cupriuretic effect between these two drugs could be due to a difference in selectivity of the drugs for different copper pools within the body.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_165ef227-6f51-479f-80f9-ea14bfa73915"></a><a name="section-2.4"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Data on the pharmacokinetics of trientine hydrochloride are not available. Dosage adjustment recommendations are based upon clinical use of the drug (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_ae305c1b-bc38-4402-858f-1505167ac41f"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">SYPRINE is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with SYPRINE is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. SYPRINE and penicillamine cannot be considered interchangeable. SYPRINE should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.</p>
<p>Unlike penicillamine, SYPRINE is not recommended in <span class="product-label-link" type="condition" conceptid="4225406" conceptname="Cystinuria">cystinuria</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in <span class="product-label-link" type="condition" conceptid="4225406" conceptname="Cystinuria">cystinuria</span>. In 15 patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, SYPRINE was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.</p>
<p>SYPRINE is not indicated for treatment of <span class="product-label-link" type="condition" conceptid="192675" conceptname="Biliary cirrhosis">biliary cirrhosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_e5d5793f-29d1-438c-8907-f5df36db0d6f"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_588257bb-e2e6-4c9f-a9ee-294fed253d91"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Patient experience with trientine hydrochloride is limited (see <a href="#CP">CLINICAL PHARMACOLOGY</a>). Patients receiving SYPRINE should remain under regular medical supervision throughout the period of drug administration. Patients (especially women) should be closely monitored for evidence of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_79565539-e594-466f-b109-cf5692e7021d"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_cde90c52-6644-468e-92b8-9c846650bc81"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">There are no reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> in patients who have been administered trientine hydrochloride for Wilson's disease. However, there have been reports of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> occurring after prolonged environmental exposure in workers who use trientine hydrochloride as a hardener of epoxy resins. Patients should be observed closely for signs of possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_2cbc2565-23ad-45a6-81d2-c3e8de3bbcdf"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be directed to take SYPRINE on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed. Because of the potential for <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, any site of exposure to the capsule contents should be washed with water promptly. For the first month of treatment, the patient should have his temperature taken nightly, and he should be asked to report any symptom such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="P_Lab"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The most reliable index for monitoring treatment is the determination of free copper in the serum, which equals the difference between quantitatively determined total copper and <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>-copper. Adequately treated patients will usually have less than 10 mcg free copper/dL of serum.</p>
<p>Therapy may be monitored with a 24-hour urinary copper analysis periodically (ie., every 6-12 months). Urine must be collected in copper-free glassware. Since a low copper diet should keep copper absorption down to less than one milligram a day, the patient probably will be in the desired state of negative copper balance if 0.5 to 1.0 milligram of copper is present in a 24-hour collection of urine.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_fac8b800-f703-416c-9844-1fb78d6a8182"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In general, mineral supplements should not be given since they may block the absorption of SYPRINE. However, <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilson's disease. If necessary, iron may be given in short courses, but since iron and SYPRINE each inhibit absorption of the other, two hours should elapse between administration of SYPRINE and iron.</p>
<p>It is important that SYPRINE be taken on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. This permits maximum absorption and reduces the likelihood of inactivation of the drug by metal binding in the gastrointestinal tract.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_57d3be5a-7ea4-4806-afc5-61c7b812305b"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Data on carcinogenesis, mutagenesis, and impairment of fertility are not available.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_81741fa2-9e50-481d-85c1-c4afdd0e972b"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_760b455f-0801-44d0-90de-b666a4ef4fc5"></a><a name="section-6.6.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Trientine hydrochloride was teratogenic in rats at doses similar to the human dose. The frequencies of both resorptions and fetal abnormalities, including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, increased while fetal copper levels decreased when trientine hydrochloride was given in the maternal diets of rats. There are no adequate and well-controlled studies in pregnant women. SYPRINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_fe8693b2-23cb-4a2e-abf2-4d0f2aad61d6"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SYPRINE is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_3addb94d-27fc-482b-b8ee-26e89811ce9e"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Controlled studies of the safety and effectiveness of SYPRINE in pediatric patients have not been conducted. It has been used clinically in pediatric patients as young as 6 years with no reported adverse experiences.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_222fd385-9ce6-4e08-ad20-04b2d8f9a39f"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of SYPRINE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience is insufficient to determine differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_542900b5-4753-42f3-86cd-c031c30fb00a"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Clinical experience with SYPRINE has been limited. The following adverse reactions have been reported in a clinical study in patients with Wilson's disease who were on therapy with trientine hydrochloride: <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (see <a href="#CP">CLINICAL PHARMACOLOGY</a>). In addition, the following adverse reactions have been reported in marketed use: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscular spasm</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>SYPRINE is not indicated for treatment of <span class="product-label-link" type="condition" conceptid="192675" conceptname="Biliary cirrhosis">biliary cirrhosis</span>, but in one study of 4 patients treated with trientine hydrochloride for <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, the following adverse reactions were reported: <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>; <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>; thickening, fissuring and flaking of the skin; <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic microcytic anemia</span>; <span class="product-label-link" type="condition" conceptid="199866" conceptname="Acute gastritis">acute gastritis</span>; aphthoid <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>; <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. A causal relationship of these reactions to drug therapy could not be rejected or established.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_64c7220c-66ab-4ad3-958c-88a9f597bee8"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is a report of an adult woman who ingested 30 grams of trientine hydrochloride without apparent ill effects. No other data on overdosage are available.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Systemic evaluation of dose and/or interval between dose has not been done. However, on limited clinical experience, the recommended initial dose of SYPRINE is 500-750 mg/day for pediatric patients and 750-1250 mg/day for adults given in divided doses two, three or four times daily. This may be increased to a maximum of 2000 mg/day for adults or 1500 mg/day for pediatric patients age 12 or under.</p>
<p>The daily dose of SYPRINE should be increased only when the clinical response is not adequate or the concentration of free serum copper is persistently above 20 mcg/dL. Optimal long-term maintenance dosage should be determined at 6-12 month intervals (see <a href="#P_Lab">PRECAUTIONS, Laboratory Tests</a>).</p>
<p>It is important that SYPRINE be given on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_0b948f20-03a9-48ac-8473-147c6435b559"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules SYPRINE, 250 mg, are light brown opaque capsules coded SYPRINE on one side and ATON 710 on the other. They are supplied as follows:</p>
<p>           <span class="Bold">NDC</span> 0187-2120-10 in bottles of 100.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_b97efdde-8ab9-434c-8f7b-f01aee72fbb3"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Keep container tightly closed.</p>
<p>Store at 2-8°C (36-46°F).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac6997c7-b991-4962-aa50-b4bcf890f291"></a><a name="section-10.1.1"></a><p></p>
<p class="First">Manufactured by:<br>Valeant Pharmaceuticals International, Inc.<br>Steinbach, MB R5G1Z7 Canada</p>
<p>For:<br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA</p>
<p>Made in Canada</p>
<p>9407800<br>LB0097-00<br>Rev. 06/14</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_842a1c7d-20b1-47fd-a548-fdb56cddf5fd"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 250 mg Capsule Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0187-2120-10</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SYPRINE<span class="Sup">® </span></span><br><span class="Bold">(TRIENTINE HYDROCHLORIDE)</span></p>
<p><span class="Bold">250 mg</span></p>
<p><span class="Bold">100</span> Capsules</p>
<p>VALEANT</p>
<div class="Figure">
<a name="id586"></a><img alt="PRINCIPAL DISPLAY PANEL - 250 mg Capsule Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c34f77a7-996b-4470-b5df-d946a7fe5dbe&amp;name=syprine-carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYPRINE 		
					</strong><br><span class="contentTableReg">trientine hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-2120</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>trientine hydrochloride</strong> (trientine) </td>
<td class="formItem">trientine hydrochloride</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Stearic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Aton;710;Syprine</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-2120-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019194</td>
<td class="formItem">11/08/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Valeant Pharmaceuticals International, Inc.</td>
<td class="formItem"></td>
<td class="formItem">253292734</td>
<td class="formItem">MANUFACTURE(0187-2120)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>430e17ae-ef84-4775-8fb9-f794cfdc52da</div>
<div>Set id: c34f77a7-996b-4470-b5df-d946a7fe5dbe</div>
<div>Version: 6</div>
<div>Effective Time: 20150112</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
